Stockscreener 앱 받기
80.77
0.02%
0.02
Apogee Therapeutics Inc 주식(APGE)의 최신 뉴스
CEO Michael Henderson Sells 20,000 Shares of Apogee Therapeutics Inc (APGE) - GuruFocus
Apogee Therapeutics CEO Henderson sells $1.6m in stock - Investing.com
Apogee Therapeutics CEO Henderson sells $1.6m in stock By Investing.com - Investing.com UK
Price-Driven Insight from (APGE) for Rule-Based Strategy - Stock Traders Daily
What are Apogee Therapeutics Incs growth leversJuly 2025 Spike Watch & Weekly Watchlist of Top Performers - baoquankhu1.vn
Is Apogee's Pipeline Momentum Driving Investor Confidence? - RTTNews
Apogee Therapeutics stock hits all-time high at 81.0 USD By Investing.com - Investing.com Nigeria
Apogee Therapeutics (NASDAQ:APGE) Sets New 52-Week HighHere's Why - MarketBeat
Apogee Therapeutics stock hits all-time high at 81.0 USD - Investing.com
Apogee Therapeutics, Inc. (APGE) Stock Analysis: Unveiling a 32.83% Potential Upside Amidst Promising Biotech Innovations - DirectorsTalk Interviews
Published on: 2026-01-13 09:29:07 - Улправда
Assessing Apogee Therapeutics (APGE) Valuation After Positive Phase 1b Asthma Trial Data And 2026 Pipeline Milestones - Yahoo Finance
SG Americas Securities LLC Invests $5.33 Million in Apogee Therapeutics Inc. $APGE - MarketBeat
Positive Asthma Data and I&I Pipeline Plans Could Be A Game Changer For Apogee Therapeutics (APGE) - Yahoo Finance
A Look At Apogee Therapeutics (APGE) Valuation After Positive Asthma Trial Update And 2026 Pipeline Milestones - Sahm
Apogee Therapeutics (NASDAQ:APGE) Insider Sells $1,455,608.00 in Stock - MarketBeat
Apogee Therapeutics CMO sells $1.45 million in shares By Investing.com - Investing.com Canada
Apogee Therapeutics CMO Carl Dambkowski Sells Shares - TradingView — Track All Markets
Apogee Therapeutics price target raised to $133 from $95 at Stifel - MSN
UBS Group Upgrades Apogee Therapeutics (NASDAQ:APGE) to Strong-Buy - MarketBeat
Apogee Therapeutics Shares Interim Asthma Data Showing Durable FeNO Drop With APG777 Single Dose - MarketBeat
What technical signals suggest for Apogee Therapeutics Inc. stockTrade Exit Report & Weekly Hot Stock Watchlists - ulpravda.ru
Can Apogee Therapeutics Inc. stock weather global recessionJuly 2025 Summary & Verified Technical Trade Signals - Улправда
Levels Update: How Apogee Therapeutics Inc. stock reacts to job market data2025 Market Trends & Fast Gaining Stock Strategy Reports - Улправда
Apogee Therapeutics (APGE) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union
What insider trading reveals about Apogee Therapeutics Inc. stock2025 Winners & Losers & Verified Momentum Stock Alerts - Улправда
UBS initiates Apogee Therapeutics stock with Buy rating, $100 target By Investing.com - Investing.com South Africa
Wolfe Research Initiates Coverage of Apogee Therapeutics (APGE) with Peer Perform Recommendation - Nasdaq
Will Apogee Therapeutics Inc. stock gain from lower inflationMarket Profile Overview & High Yield Portfolio Picks - Улправда
Craig-Hallum raises Apogee Therapeutics stock price target on promising asthma data - Investing.com Nigeria
March 20th Options Now Available For Apogee Therapeutics (APGE) - Nasdaq
Apogee Therapeutics Inc Stock Analysis and ForecastInstitutional Holding Changes & High Yield Trading Signals - earlytimes.in
UBS initiates Apogee Therapeutics stock with Buy rating, $100 target - Investing.com
Apogee Therapeutics CFO Sells 8,000 Shares - TradingView — Track All Markets
Wolfe Research initiates coverage on Apogee Therapeutics stock with Peerperform rating By Investing.com - Investing.com South Africa
Wolfe Research initiates coverage on Apogee Therapeutics stock with Peerperform rating - Investing.com Nigeria
Apogee Therapeutics stock price target raised to $137 by BTIG on asthma data - Investing.com South Africa
One Shot, Six Months of Asthma Relief? Apogee Drug Shows Strong, Long-Lasting Effect In Trial - Benzinga
Apogee Therapeutics (NASDAQ:APGE) Shares Gap DownWhat's Next? - MarketBeat
Apogee Therapeutics stock maintains Outperform rating at RBC on asthma data By Investing.com - Investing.com South Africa
Apogee Therapeutics stock maintains Outperform rating at RBC on asthma data - Investing.com Nigeria
Apogee Therapeutics stock falls after asthma trial data - Investing.com
Apogee Therapeutics stock falls after asthma trial data By Investing.com - Investing.com South Africa
Apogee Therapeutics Announces Positive Interim Data from Phase 1b Trial of Zumilokibart - TradingView — Track All Markets
Apogee Therapeutics to report interim asthma trial results By Investing.com - Investing.com Nigeria
Apogee Therapeutics Reports Positive Phase 1b Data For Zumilokibart In Mild-to-moderate Asthma - Nasdaq
Apogee Therapeutics rises as asthma drug shows promise in early trial - TradingView — Track All Markets
Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook - The Manila Times
4.73%
0.92%
자본화:
|
볼륨(24시간):